• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性非甲非乙型肝炎:生化活性与形态学活性之间缺乏相关性,以及免疫抑制疗法对疾病进展的影响。

Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease progression.

作者信息

Schoeman M N, Liddle C, Bilous M, Grierson J, Craig P I, Batey R G, Farrell G C

机构信息

Westmead Hospital, NSW, Australia.

出版信息

Aust N Z J Med. 1990 Feb;20(1):56-62. doi: 10.1111/j.1445-5994.1990.tb00372.x.

DOI:10.1111/j.1445-5994.1990.tb00372.x
PMID:2108661
Abstract

A study was made of 52 patients considered to probably have chronic non-A, non-B hepatitis who were seen during an eight-year period at Westmead Hospital, Sydney. The patients were followed for a median of 28 months to assess the natural history of the disease and, in a small number of patients, the effect of immunosuppressive therapy on disease progression was examined. In 94% of cases, infection appeared to have been acquired by a parenteral route; the remainder were sporadic infections. Fifty-six per cent of the patients had mild constitutional symptoms and the remainder were asymptomatic. Similarly, 54% of patients had no signs of chronic liver disease and none exhibited signs of hepatic decompensation. Liver biopsies were performed in 42 patients; chronic active hepatitis with or without cirrhosis was present in 90%. However, neither the presence of symptoms nor the degree of biochemical abnormality were predictive of disease severity as determined histologically. Among eight patients treated with corticosteroids (with or without azathioprine), six underwent follow-up liver biopsy. Quantitative analysis of inflammatory and fibrotic changes indicated significant (p less than 0.01) progression of histological severity during a median 33 months (range 7-98 months) between biopsies with cirrhosis developing in four instances. In contrast, among the seven untreated patients rebiopsied after a median of 16.0 months (range 11-37 months) there was no overall change in histological severity and only one patient developed cirrhosis. it is concluded that histological assessment is required in all patients suspected of having chronic non-A, non-B hepatitis as other means of assessment are unreliable.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对悉尼韦斯特米德医院八年间收治的52例疑似慢性非甲非乙型肝炎患者进行了一项研究。对这些患者进行了为期28个月的中位数随访,以评估疾病的自然史,并且对少数患者,研究了免疫抑制疗法对疾病进展的影响。在94%的病例中,感染似乎是通过肠道外途径获得的;其余为散发性感染。56%的患者有轻度全身症状,其余患者无症状。同样,54%的患者没有慢性肝病体征,也没有出现肝失代偿体征。对42例患者进行了肝活检;90%的患者存在伴有或不伴有肝硬化的慢性活动性肝炎。然而,症状的存在与否以及生化异常的程度均不能预测组织学所确定的疾病严重程度。在8例接受皮质类固醇(联合或不联合硫唑嘌呤)治疗的患者中,6例接受了随访肝活检。炎症和纤维化变化的定量分析表明,在两次活检之间的33个月中位数(范围7 - 98个月)期间,组织学严重程度有显著进展(p小于0.01),4例出现肝硬化。相比之下,在7例未经治疗的患者中,在16.0个月中位数(范围11 - 37个月)后再次活检,组织学严重程度没有总体变化,只有1例患者发展为肝硬化。得出的结论是,所有疑似慢性非甲非乙型肝炎的患者都需要进行组织学评估,因为其他评估方法不可靠。(摘要截短至250字)

相似文献

1
Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease progression.慢性非甲非乙型肝炎:生化活性与形态学活性之间缺乏相关性,以及免疫抑制疗法对疾病进展的影响。
Aust N Z J Med. 1990 Feb;20(1):56-62. doi: 10.1111/j.1445-5994.1990.tb00372.x.
2
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.数字图像分析评估肝移植后复发性 HCV 纤维化进展的胶原。
J Hepatol. 2013 May;58(5):962-8. doi: 10.1016/j.jhep.2012.12.016. Epub 2012 Dec 20.
3
Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.在一项关于他克莫司单药治疗与三联治疗的随机试验中,肝移植后复发性丙型肝炎病毒的结果。
Liver Transpl. 2009 Dec;15(12):1783-91. doi: 10.1002/lt.21907.
4
Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis.自身免疫性慢性活动性肝炎患者的生存率及纤维化的组织学消退情况。
J Hepatol. 1993 Apr;18(1):15-23. doi: 10.1016/s0168-8278(05)80005-4.
5
The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis.不同免疫抑制措施在丙型肝炎肝硬化肝移植术后丙型肝炎病毒再感染的长期组织学转归中的作用。
Transplantation. 2001 Aug 15;72(3):412-8. doi: 10.1097/00007890-200108150-00009.
6
A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients.台湾慢性非甲非乙型(丙型)肝炎的临床病理研究:输血后患者与散发性患者的比较。
J Hepatol. 1994 Aug;21(2):244-9. doi: 10.1016/s0168-8278(05)80403-9.
7
Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens.原位肝移植术后丙型肝炎的组织学复发与进展:免疫抑制方案的影响
Liver Transpl. 2001 Dec;7(12):1056-63. doi: 10.1053/jlts.2001.27803.
8
Azathioprine for long-term maintenance of remission in autoimmune hepatitis.硫唑嘌呤用于自身免疫性肝炎缓解期的长期维持治疗。
N Engl J Med. 1995 Oct 12;333(15):958-63. doi: 10.1056/NEJM199510123331502.
9
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病:英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
10
Application of a numerical scoring system for assessment of histological outcome in patients with chronic posttransfusion non-A, non-B hepatitis with or without antibodies to hepatitis C.
Liver. 1990 Oct;10(5):257-63. doi: 10.1111/j.1600-0676.1990.tb00467.x.

引用本文的文献

1
Approach to recurrent hepatitis C following liver transplantation.肝移植后复发性丙型肝炎的处理方法
Curr Gastroenterol Rep. 2007 Mar;9(1):23-30. doi: 10.1007/s11894-008-0017-8.
2
The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985.1961年至1985年间感染丙型肝炎病毒的血友病患者队列中丙型肝炎病毒的自然史。
Gut. 2000 Dec;47(6):845-51. doi: 10.1136/gut.47.6.845.
3
Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection.慢性丙型肝炎病毒感染中肝内细胞毒性T淋巴细胞反应的特征
Springer Semin Immunopathol. 1997;19(1):69-83. doi: 10.1007/BF00945026.
4
Risks and benefits of interferon-alpha in the treatment of hepatitis.α干扰素治疗肝炎的风险与益处
Drug Saf. 1995 Nov;13(5):304-16. doi: 10.2165/00002018-199513050-00004.
5
Histological patterns of prolonged hepatitis C infection.
Gastroenterol Jpn. 1993 May;28 Suppl 5:37-41. doi: 10.1007/BF02989202.
6
Epidemiology of hepatitis C virus infection in Australia.
Gastroenterol Jpn. 1993 May;28 Suppl 5:32-6. doi: 10.1007/BF02989201.
7
Prediction of response to interferon in patients with chronic active hepatitis C, and evidence that this improves hepatic metabolic function.慢性丙型活动性肝炎患者对干扰素反应的预测,以及干扰素可改善肝脏代谢功能的证据。
Gastroenterol Jpn. 1991 Jul;26 Suppl 3:243-6. doi: 10.1007/BF02779310.